Target intelligence / Profile preview

Host intestinal epithelial cells and gut-associated lymphoid tissue (IEC/GALT)

Target
IEC/GALT
Molecular classification
Other
01

Overview

Host intestinal epithelial cells (IECs) and gut-associated lymphoid tissue (GALT) represent the integrated structural and immunological components of the gastrointestinal barrier. IECs form a single-layer mucosal surface that regulates nutrient absorption and provides a physical defense against luminal pathogens through tight junctions and mucus secretion (Okumura & Takeda, 2017, Nature Reviews Immunology). GALT, comprising Peyer's patches, isolated lymphoid follicles, and mesenteric lymph nodes, functions as the body's largest immune compartment, responsible for inducing oral tolerance and secreting secretory IgA (Mowat & Agace, 2014, Nature Reviews Immunology). This system is a primary site of pathology in inflammatory bowel diseases (IBD) and serves as a critical reservoir for HIV-1 replication and CD4+ T-cell depletion (Brenchley & Douek, 2008, Immunity). Pharmacological targeting of this environment often involves biologics like Vedolizumab, which inhibits the alpha4beta7 integrin to prevent lymphocyte trafficking specifically to the GALT (Feagan et al., 2013, NEJM).

Other names
Intestinal mucosaGut immune systemGastrointestinal lymphoid tissueIntestinal barrierGut-associated immune system
02

Mechanism of action

Therapeutic strategies involve the inhibition of lymphocyte trafficking to the gut, neutralization of pro-inflammatory cytokines (e.g., TNF-alpha, IL-12/23), and the maintenance of mucosal barrier integrity.

03

Biological functions

Immune responseBarrier functionAntigen presentationNutrient absorptionHomeostasisOral tolerance
04

Disease associations

Inflammatory bowel diseaseInfectionCeliac diseaseHIV/AIDSColorectal cancerFood allergy
05

Safety considerations

Increased risk of opportunistic infectionsLoss of mucosal integrityImmunogenicity to biologicsPotential for localized malignancyProgressive multifocal leukoencephalopathy (rare)
06

Interacting drugs

Vedolizumab

7 more in the full profile.

07

Biomarkers

Fecal calprotectinFecal lactoferrinC-reactive proteinIntestinal fatty acid-binding protein (I-FABP)Citruilline

Beyond the preview

Go deeper on Host intestinal epithelial cells and gut-associated lymphoid tissue (IEC/GALT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host intestinal epithelial cells and gut-associated lymphoid tissue (IEC/GALT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call